|1.||Klinman, Dennis M: 25 articles (01/2015 - 06/2002)|
|2.||Krieg, Arthur M: 17 articles (08/2011 - 06/2002)|
|3.||Levine, Jon D: 13 articles (01/2015 - 02/2004)|
|4.||Ishii, Ken J: 9 articles (10/2015 - 08/2002)|
|5.||Morishita, Ryuichi: 9 articles (12/2014 - 08/2003)|
|6.||Kaneda, Y: 9 articles (06/2006 - 07/2000)|
|7.||Kline, Joel N: 8 articles (10/2008 - 07/2002)|
|8.||Morishita, R: 8 articles (06/2006 - 05/2000)|
|9.||Weiner, George J: 7 articles (07/2014 - 02/2002)|
|10.||Balsari, Andrea: 7 articles (07/2013 - 08/2004)|
10/01/2009 - "Until now, the anti-tumor efficacy of synthetic oligodeoxynucleotides containing CpG motifs (CpG ODNs) has been reported in a number of preventive and therapeutic tumor models. "
01/01/2013 - "Locally injected immunostimulatory oligodeoxynucleotides containing CpG motifs (CpG-ODNs), which are TLR9 agonists, have shown promise in cancer models. "
08/15/2007 - "Although the efficacy of CpG oligodeoxynucleotides has been thought to depend on the expression of TLR9, we unexpectedly found that tumor rejection did not require host expression of TLR9. "
12/01/2013 - "Our previous studies demonstrated that anti-CD40 mAb (anti-CD40) can synergize with CpG oligodeoxynucleotides (CpG) to mediate antitumor effects by activating myeloid cells, such as macrophages in tumor-bearing mice. "
07/01/2013 - "Recent studies have suggested that the anti-cancer activity of CpG-oligodeoxynucleotides (CpG-ODNs) is owing to their immunomodulatory effects in tumor-bearing host. "
08/15/2011 - "Intranasal delivery of CpG oligodeoxynucleotides also provided significant protection; however, combining preexposure vaccination with CpG treatment at the time of infection or up to 18 hours after infection, provided significantly greater protection than either treatment alone. "
08/01/1996 - "As infection and replication of HBV mainly occur in liver parenchymal cells, selective targeting of antiviral nucleoside analogues as well as antisense oligodeoxynucleotides to the liver would theoretically improve therapeutic efficacy. "
09/13/2005 - "Treatment with synthetic oligodeoxynucleotides containing CpG motifs (CpG ODNs) is remarkably protective against otherwise lethal infection. "
05/01/2005 - "In the present study, we elucidated the effect of synthetic CpG-containing oligodeoxynucleotides (ODN) on pulmonary and disseminated infection caused by Cryptococcus neoformans. "
01/01/2014 - "Intraperitoneal prophylaxis with CpG oligodeoxynucleotides protects neutropenic mice against intracerebral Escherichia coli K1 infection."
|3.||Autoimmune Diseases (Autoimmune Disease)
03/01/2013 - "Synthetic suppressive oligodeoxynucleotides (ODNs) expressing TTAGGG motifs selectively reduce Th1 cytokine production and have been proven effective in T helper type 1 (Th1)-mediated autoimmune diseases. "
08/01/2008 - "Recent findings indicate that suppressive oligodeoxynucleotides (ODNs) expressing TTAGGG motifs selectively reduce Th1 cytokine production and have been proven effective at blocking the development of organ-specific autoimmune diseases. "
04/01/2005 - "Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?"
07/01/2007 - "The inhibition of immune responses by regulatory oligodeoxynucleotides may be useful for the treatment of immune-mediated disorders including autoimmune diseases and graft rejection."
12/01/2014 - "Suppressive oligodeoxynucleotides (Sup ODN) express repetitive TTAGGG motifs that have proven useful in the treatment/prevention of numerous inflammatory and autoimmune diseases. "
01/01/2015 - "CpG oligodeoxynucleotides have been investigated in airway allergy studies, but even if promising, efficacy requires further substantiation. "
04/01/2014 - "In addition, intrathecal treatment with TSP4 antisense, but not mismatch, oligodeoxynucleotides blocked both injury-induced TSP4 up-regulation in Vc/C2 and behavioural hypersensitivity. "
04/01/2014 - "TSP4 antisense and mismatch oligodeoxynucleotides were intrathecally injected into injured rats to see if antisense oligodeoxynucleotide treatment could reverse injury-induced TSP4 up-regulation and orofacial behavioural hypersensitivity. "
09/12/2007 - "After Kv3.4 or Kv4.3 expression in lumbar DRG neurons was suppressed by intrathecal injections of antisense oligodeoxynucleotides, mechanical but not thermal hypersensitivity developed. "
12/01/2004 - "Synthetic oligodeoxynucleotides containing unmethylated CG dinucleotides (CpG) are strong T(H)1 adjuvants and are being investigated for allergy immunotherapy. "
11/01/2007 - "We investigated the therapeutic efficacy of in vivo DC activation, by directly administering glioma cell lysate with CpG oligodeoxynucleotides (CpG/lysate), in glioma-bearing mice. "
08/01/2007 - "c-Met antisense oligodeoxynucleotides as a novel therapeutic agent for glioma: in vitro and in vivo studies of uptake, effects, and toxicity."
08/01/2007 - "These data are encouraging for further study of c-Met antisense oligodeoxynucleotides as a therapeutic modality for glioma."
08/01/2007 - "To study the uptake of oligodeoxynucleotides (ODNs) by glioma cells in vitro, cultured glioma cells readily incorporated caroboxyfluorescein-5-succimidyl ester (FAM) labeled phosphorothioate oligodeoxynucleotides, as demonstrated by immunofluorescence microscopy and flow cytometry. "
05/15/2001 - "In vitro studies using antisense oligodeoxynucleotides and integrin activation confirmed the role of P311 in supporting migration of malignant glioma cells. "
|2.||Messenger RNA (mRNA)
|6.||NF-kappa B (NF-kB)
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|10.||DNA (Deoxyribonucleic Acid)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Combination Drug Therapy (Combination Chemotherapy)